Lepu Biopharma Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

Lepu Biopharma şirketinin toplam hissedar öz sermayesi CN¥902.0M ve toplam borcu CN¥729.6M olup, bu da borç-öz sermaye oranını 80.9% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla CN¥2.4B ve CN¥1.5B dir.

Anahtar bilgiler

80.9%

Borç/özkaynak oranı

CN¥729.61m

Borç

Faiz karşılama oranı	n/a
Nakit	CN¥586.22m
Eşitlik	CN¥902.01m
Toplam yükümlülükler	CN¥1.54b
Toplam varlıklar	CN¥2.44b

Son finansal sağlık güncellemeleri

Lepu Biopharma (HKG:2157) Is Making Moderate Use Of Debt

Aug 23

Recent updates

Lepu Biopharma (HKG:2157) Is Making Moderate Use Of Debt

Aug 23

The Price Is Right For Lepu Biopharma Co., Ltd. (HKG:2157) Even After Diving 27%

Jul 18

Lepu Biopharma Co., Ltd. (HKG:2157) Stocks Pounded By 27% But Not Lagging Industry On Growth Or Pricing

Jun 03

Revenues Not Telling The Story For Lepu Biopharma Co., Ltd. (HKG:2157) After Shares Rise 26%

Apr 15

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: 2157 'nin kısa vadeli varlıkları ( CN¥744.1M ) kısa vadeli yükümlülüklerini ( CN¥985.8M ) kapsamıyor.

Uzun Vadeli Yükümlülükler: 2157 şirketinin kısa vadeli varlıkları ( CN¥744.1M ) uzun vadeli yükümlülüklerini ( CN¥553.2M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: 2157 'nin net borç/öz sermaye oranı ( 15.9% ) tatmin edici olarak değerlendirilmektedir.

Borcun Azaltılması: 2157 şirketinin borç/öz sermaye oranının son 5 yılda azalıp azalmadığını belirlemek için yeterli veri yok.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: 2157 şirketinin mevcut serbest nakit akışına göre bir yıldan fazla yetecek nakit pisti bulunmaktadır.

Tahmini Nakit Akışı: 2157 serbest nakit akışı her yıl % { 19.3 1.2 |round(1)}} yıl boyunca yeterli nakit akışına sahip olacaktır.

Lepu Biopharma Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Lepu Biopharma (HKG:2157) Is Making Moderate Use Of Debt

Recent updates

Lepu Biopharma Co., Ltd. Receives the Acceptance Notice Issued by China National Medical Products Administration

First half 2024 earnings released: CN¥0.12 loss per share (vs CN¥0.086 loss in 1H 2023)

New major risk - Financial position

First half 2024 earnings released: CN¥0.12 loss per share (vs CN¥0.086 loss in 1H 2023)

Lepu Biopharma (HKG:2157) Is Making Moderate Use Of Debt

Lepu Biopharma Co., Ltd. to Report First Half, 2024 Results on Aug 21, 2024

Lepu Biopharma Co., Ltd. Announces Breakthrough Therapy Designation Granted by the FDA to MRG003 for the Treatment of R/M NPC

The Price Is Right For Lepu Biopharma Co., Ltd. (HKG:2157) Even After Diving 27%

Lepu Biopharma Co., Ltd. (HKG:2157) Stocks Pounded By 27% But Not Lagging Industry On Growth Or Pricing

New minor risk - Shareholder dilution

Lepu Biopharma Co., Ltd. Announces Three Clinical Trial Results Presented At 2024 Asco Annual Meeting

Lepu Biopharma Co., Ltd. has filed a Follow-on Equity Offering in the amount of HKD 234.3586 million.

Full year 2023 earnings released: CN¥0.013 loss per share (vs CN¥0.42 loss in FY 2022)

Lepu Biopharma Co., Ltd., Annual General Meeting, Jun 19, 2024

Revenues Not Telling The Story For Lepu Biopharma Co., Ltd. (HKG:2157) After Shares Rise 26%

Lepu Biopharma Co., Ltd. to Report Fiscal Year 2023 Results on Mar 27, 2024

Lepu Biopharma Co., Ltd. Receives Fast Track Designation by the Food and Drug Administration of the United States for the Treatment of Pancreatic Cancer

New minor risk - Share price stability

Lepu Biopharma Co., Ltd. Announces Completion of Patient Enrollment of Pivotal Phase IIb Clinical Trial for MRG003 for the Treatment of R/M NPC

Lepu Biopharma Co., Ltd. Announces Orphan-Drug Designation Granted by the FDA to MRG004A for the Treatment of Pancreatic Cancer

Lepu Biopharma Co., Ltd. to Report First Half, 2023 Results on Aug 25, 2023

Lepu Biopharma Co., Ltd. Provides Update on the Data from Phase Ia Clinical Study of CMG901

Less than half of directors are independent

Lepu Biopharma Co., Ltd. Announces Conditional Marketing Approval Obtained in China Forpuyouheng (Pucotenlimab Injection) for Thetreatment of Inoperable or Metastatic Melanoma

Lepu Biopharma Co., Ltd. to Report First Half, 2022 Results on Aug 25, 2022

Anti-PD-1 Monoclonal Antibody Puyouheng Co-developed by LEPU BIOPHARMA and HANX BIOPHARMACEUTICALS Approved for Marketing in China by NMPA

Lepu Biopharma Co., Ltd. Receive Conditional Marketing Approval Obtained in China for Puyouheng (Pucotenlimab Injection) for the Treatment Inhigh Levels of Microsatellite Instability/Deficient Mismatch Repair (MSI-H/dMMR)

Less than half of directors are independent

Lepu Biopharma Co., Ltd., Annual General Meeting, Jun 21, 2022

Lepu Biopharma Co., Ltd. has completed an IPO in the amount of HKD 904.62588 million.

Less than half of directors are independent

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin